Lana Medical Co. (9587) fair value: what the stock is really worth
We calculate from audited financials what Lana Medical Co. is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Lana Medical Co. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
33‑month range 1.90 SAR – 1,000,000 SAR · fair‑value band 0.8200 SAR – 1.37 SAR · the 2.01 SAR price screens above the 1.10 SAR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.
Lana Medical Company provides medical services to healthcare sector in the Kingdom of Saudi Arabia. The company operates through five segments: Medical Waste Management, Sale of Medical Equipment, Sale of Medical Supplies, Construction, and Rental.
Show more
Lana Medical Company provides medical services to healthcare sector in the Kingdom of Saudi Arabia. The company operates through five segments: Medical Waste Management, Sale of Medical Equipment, Sale of Medical Supplies, Construction, and Rental. It offers medical devices, including laser hair removal, C02 fractional laser technology, non-surgical HIFU tightening technique, and skin care. The company also provides medical equipment maintenance; medical supplies; and health care products, including emergency coverage for construction sites and medical services for industrial facilities and cities, medical coverage for projects and events, equipping and operating primary medical clinics, private ambulance services, home hemodialysis services, and health escort rental services. In addition, it offers infection control solutions; and medical and industrial, pharmaceutical and pharmaceutical, chemical, and slaughterhouse waste management, as well as carbon ash management, non-hazardous waste, public health pests, food health and safety, and environmental consulting services. Further, the company is involved in dealing with transfer and disposal of hazardous and organic waste services; construction of residential and non-residential buildings; leasing of containers for transportation of construction debris; production of plastic supplies; and construction waste management and investment services. Additionally, it engages in the maintenance and cleaning of hospitals, medical centers, and general medical complexes; import and export activities; operation of hazardous medical waste treatment facilities and final disposal of hazardous waste; separating and sorting metal and non-metal waste, and scraps and other articles into secondary raw materials; and retail sale of medical equipment, tools, and supplies. Lana Medical Company was founded in 2010 and is based in Riyadh, the Kingdom of Saudi Arabia.
Stock analysis
Lana Medical Co. (9587) currently trades at 2.01 SAR, while our model-based Fair Value estimate is 1.10 SAR, implying the stock looks roughly 82.7% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 2.18 SAR per share, and 3 of the 15 models we run sit above the 2.01 SAR price.
Bear case: the Economic Profit group reads lowest at 0.7500 SAR, and 12 of the 15 models stay below the price. Evidence for this calculation is low.
Scenario range: 0.8200 SAR (bear) to 1.37 SAR (bull), the price of 2.01 SAR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Lana Medical Co. reported revenue of 92.3M SAR in FY2025 versus 32.0M SAR in FY2021, a compound +30.4%/yr. Reported net income was 2.7M SAR in FY2025, compounding −20.0%/yr from FY2021.
Key figures
Market cap 135M SAR (≈ $36.0M) · P/E ratio 40.2 · P/S ratio 1.17 · EPS (TTM) 0.0500 SAR · Net margin 2.9% · Return on equity 4.3% · Return on assets (EBIT) 7.5% · Operating margin 7.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −45%, 9587 screens richer than that median.
Fair Value models
Bear 0.8200 SARFair Value 1.10 SARBull 1.37 SAR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 8 months old). Earnings retained since then (0.0353 SAR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+9.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+31.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+34.4%
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.0%
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−18.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−18.6%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.22% → 7%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 80 stocks
Beats the industry median on 7/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score28 · Bottom 25%
Fair Value upside−54% · Bottom 25%
Profitability
Return on equity (TTM)4% · Below median
Return on assets3% · Above median
Net margin (TTM)3% · Above median
Operating margin (TTM)8% · Top 25%
Growth and dividend
Revenue growth−12% · Bottom 25%
Balance sheet
Debt / equity0.06× · Below median
Valuation Multiplesvs Medical Distribution median · lower = cheaper
P/E (TTM)40.2× · Priciest 25%
P/B0.55× · Cheapest 25%
P/S (TTM)0.39× · Cheaper than median
EV/EBITDA3.4× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 20
FUTURE (revenue growth)0· sector 16
PAST (return on equity)17· sector 23
HEALTH (low debt)97· sector 97
DIVIDEND (yield)0· sector 59
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Lana Medical Co. Fair Value". https://www.fairvalue-calculator.com/stock/9587
Frequently asked questions
Is Lana Medical Co. (9587) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of 1.10 SAR versus a price of 2.01 SAR, about −45% upside (overvalued).
What is the fair value of 9587?
Our model-based fair value for Lana Medical Co. is 1.10 SAR (as of Sep 13, 2026), built from audited fundamentals. The current price: 2.01 SAR.
What is the quality score of 9587?
Lana Medical Co. has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Lana Medical Co. (9587)?
Our model-based price target is the fair value of 1.10 SAR (as of Sep 13, 2026) from 15 valuation models. Cautious scenario 0.8200 SAR, optimistic scenario 1.37 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the Lana Medical Co. stock forecast for 2026?
Our models put fair value at 1.10 SAR, about −45% upside versus a price of 2.01 SAR (overvalued). Cautious scenario 0.8200 SAR, optimistic scenario 1.37 SAR. The calculation is refreshed regularly with new filings.
What is the revenue of Lana Medical Co. (9587)?
Lana Medical Co. reported trailing-twelve-month revenue of about 92.3M SAR (latest available figure, as of Sep 13, 2026).
What is the intrinsic value of Lana Medical Co. (9587)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lana Medical Co. it is 1.10 SAR per share (as of Sep 13, 2026), against a price of 2.01 SAR. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Lana Medical Co. stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 9587 trades above its calculated fair value: price 2.01 SAR, fair value 1.10 SAR, a gap of about −45% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 9587?
No. The price is what the market pays today (2.01 SAR); the fair value is what the company's own numbers justify (1.10 SAR). For Lana Medical Co. the two are 0.9100 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is Lana Medical Co. worth?
The market values Lana Medical Co. at about 135M SAR (market capitalisation, as of Sep 13, 2026). Per share that is 2.01 SAR; our models calculate a fair value of 1.10 SAR per share.
What do the bullish and bearish scenarios say about 9587?
Our models span a range for Lana Medical Co.: cautious scenario 0.8200 SAR, base 1.10 SAR, optimistic 1.37 SAR per share (as of Sep 13, 2026, price 2.01 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 9587?
Lana Medical Co. trades at a price-to-earnings ratio of 40.2 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 1.10 SAR is built from several models across several years. Other multiples: P/B 0.6, P/S 0.4, EV/EBITDA 3.4.
How solid is the balance sheet of Lana Medical Co. (9587)?
Balance-sheet figures for Lana Medical Co. (as of Sep 13, 2026): return on equity 4.3%, debt of 0.06 per unit of equity. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
Which stocks are comparable to Lana Medical Co.?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Lana Medical Co. stock attractive at the current price?
The data as of Sep 13, 2026: price 2.01 SAR, calculated fair value 1.10 SAR (−45%), Quality Score 28/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 9587 calculated?
We run Lana Medical Co. through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1.10 SAR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.6 % above its aggregate fair value. Lana Medical Co. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Lana Medical Co. (9587)?
The closing price on Sep 14, 2026 was 2.01 SAR. Our model-based fair value is 1.10 SAR, about −45% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Lana Medical Co. right now?
The price sits above even our optimistic bull case (1.37 SAR). The favourable scenario is already priced in. Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Lana Medical Co.
How large is the market capitalisation of Lana Medical Co. (9587)?
The market capitalisation of Lana Medical Co. is 135M SAR (≈ $36.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Lana Medical Co. (9587)?
The price-to-sales ratio of Lana Medical Co. is 1.17 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Lana Medical Co. (9587)?
Earnings per share at Lana Medical Co. are 0.0500 SAR (price ÷ EPS = P/E 40.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Lana Medical Co. (9587)?
The net margin of Lana Medical Co. is 2.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Lana Medical Co. (9587)?
The return on equity (ROE) of Lana Medical Co. is 4.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Lana Medical Co. (9587)?
On an EBIT basis the return on assets of Lana Medical Co. is 7.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Lana Medical Co. (9587)?
The operating margin of Lana Medical Co. is 7.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Lana Medical Co. (9587)?
Revenue at Lana Medical Co. is growing −11.6% versus a year earlier (3y avg +31.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Lana Medical Co. (9587)?
Earnings per share at Lana Medical Co. are growing −92.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Lana Medical Co. (9587) generate?
The free cash flow of Lana Medical Co. is −10.4M SAR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Lana Medical Co. (9587) carry?
The net debt of Lana Medical Co. is 15.7M SAR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Lana Medical Co. in the live analysis
One click puts Lana Medical Co. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
